A major pharmaceutical industry group is urging the Biden administration to withdraw a plan for the government to license patents on expensive drugs to third-party companies for cheaper manufacturing.
The Biden administration’s proposed framework to “march in” on government-funded patents because the drugs they cover are too expensive would threaten the US pipeline of investments and innovation, the Pharmaceutical Research and Manufacturers of America said Tuesday.
“The negative effects of the Draft Framework could have a ripple effect throughout the innovation ecosystem, ultimately reducing investment in small biotech companies and in the development of university inventions, and jeopardizing future benefits ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.